3D CELL CULTURE MARKET ANALYSIS

3D Cell Culture Market, By Technology (Extracellular Matrices or Scaffolds, Bioreactors, Gels, Scaffold-free Platforms, Microchips), By Application (Research, Drug Discovery, Tissue Engineering, Clinical Applications, Stem Cell Biology), By End User (Research Labs & Institutes, Biopharmaceutical Industry, Hospitals And Diagnostic Centers, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Nov 2023
Code : CMI534
Pages :172
Formats :
Excel and PDF
Industry : Biotechnology

Market News

In August 2021, Amerigo Scientific, a distribution company providing critical products and services to the biomedical and life science research companies, expanded its cell culture portfolio with the launch of 3D cell culture for scientific uses. This new 3D cell culture system can used in research areas such as drug discovery, medicine, evaluation of nanomaterials, and basic life science.
In August 2020, Corning Incorporated, a U.S.-based multinational technology company, announced the launch of its 3D Clear Tissue Clearing Reagent, allowing for rapid and easy imaging of tissues in 3D cell culture without damaging the underlying cellular morphology. This solution, manufactured and sold by Visikol, is now commercially available through Corning and adds to the company’s 3D cell culture portfolio.
In October 2020, Merck, a leading science and technology company, announced that it is collaborating with D1Med, a Shanghai, China-based biopharmaceutical start-up precision-medical company, to accelerate production of D1Med’s 3D cell culture technology applications used in the drug discovery process.
In March 2022, CELLINK a part of BICO, a bioconvergence startup, launched BIO CELLX, a first of its kind biodispensing platform used to automate 3D cell culture. By providing cell biologists with pre-validated protocols, the BIO CELLX eliminates barriers for automating 3D cell-based assays that target cancer research and drug discovery.
On June 14, 2023, Sartorius, an international pharmaceutical and laboratory equipment provider and Stanford University, a private research university in Stanford, California, U.S. extended their collaboration to develop a scalable platform for large-scale human iPSC production.